Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement

Thrombosis and Haemostasis

Volumn 80, Issue 6, 1998, Pages 994-1001

  Gawaz, Meinrad ^a,c   Ruf, Andreas ^b   Neumann, Franz Josef ^a   Pogátsa Murray, Gisela ^a   Dickfeld, Timm ^a   Zohlnhöfer, Dietlind ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Klinikum Karlsruhe   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; MEMBRANE PROTEIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; STENT; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE;

EID: 0031732864     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615400     Document Type: Article

References (36)

1. Gawaz M, Neumann FJ, Ott I, May A, Rüdiger S, Schömig A. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron Art Dis 1997; 8: 121-8.
2. Neumann FJ, Gawaz M, Ott I, May A, Mössmer G, Schömig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996; 27: 15-21.
3. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzki M, Walter H, Zitzmann-Roth EM, Richard G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary stents. N Engl J Med 1996; 334: 1084-9.
4. Leon MB, Baim DS, Gordon P. Clinical and angiographic results from the stent anticoagulation regimen study (STARS) [abstract]. Circulation 1996; 94: I-685.
5. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 1994; 330: 956-61.
6. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.
7. IMPACT-II Investigators. Effects of competitive platelet glycoprotein IIb/IIIa inhibition with velofibatide (integrilin) in reducing complications of percutaneous coronary intervention: results of the randomized clinical trial IMPACT-II. Lancet 1997; 349: 1422-8.
8. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
9. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina in acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
10. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 95: 809-13.
11. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, Guillin MC, Eldor A. The procoagulant activity of red cells from patients with β-thalassemia major correlates with in-vivo platelet activation. Brit J Haematol 1997; 98: 51-6.
12. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-15.
13. Born GVR, Cross GP. Effect of inorganic ions and of plasma proteins on the aggregation of blood platelets by adenosine diphosphate. J Physiol 1964; 170: 397-414.
14. Jin Y, Dietz HC, Nurden A, Bray PF. Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa. Blood 1993; 82: 2281-8.
15. O'Toole TE, Loftus JC, Du X, Glass AA, Ruggeri ZM, Shattil SJ, Plow EF. Ginsberg MH. Affinity modulation of the aIIbb3 integrin (platelet GPIIb-IIIa) is an intrinsic property of the receptor. Cell Regulation 1990; 1: 883-93.
16. Gawaz M, Loftus JC, Bajt ML, Frojmovic MM, Plow EF, Ginsberg MH. Ligand bridging mediates integrin alpha IIb beta 3 (platelet GPIIb-IIIa) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest 1991; 88: 1128-34.
17. Gawaz M, Mayinger P, Neumann FJ. Effects ofadenosine-5'-triphosphate (ATP) on ligand recognition of platelet fibrinogen receptor on GPIIb-IIIa. Am J Physiol 1994; 267: H1098-H1106.
18. Frelinger AL, Cohen I, Plow EF, Smith MA, Roberts J, Lam SCT, Ginsberg MH. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 1990; 260: 6346-52.
19. Woods VL, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complexes which may be accessible to some but not other extracellular proteins. J Biol Chem 1986; 261: 15242-51.
20. Ginsberg MH, Frelinger AL, Lam SCT, Forsyth J, McMillan R, Plow EF, Shattil SJ. Analysis of platelet aggregation disorders based on flow cytometric analysis of platelet membrane glycoprotein IIb-IIIa with conformation specific monoclonal antibodies. Blood 1990; 76; 2017-23.
21. Kereiakes DJ, Lincoff AM, Simoons ML, deBoer MJ, Tcheng JE, Vahanian A, Anderson KM, Weisman HF, Califf RA, Topol EJ. Complementarity of stenting and abciximab for percutaneous coronary interventions. JACC 1998; 31: 54A.
22. Harker A, Bruno JJ. Ticlopidine's mechanism of action on human platelets. In: Hass K, Easton JD, eds. Ticlopidine, Platelets and Vascular Disease. New York, NY: Springer-Verlag; 1993: 99-116.
23. McFarland JG. Platelet immunology and alloimmunization. In: E Rossi, TL Simon, GS Mors, Gould SA eds. Principles of transfusion medicine. Baltimore: Williams & Wilkins, Second edition 1996.
24. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996; 78: 1161-6.
25. Christopoulos CG, Machin SJ. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody. Br J Haematol 1994; 87: 650-2.
26. Bednar B, Bednar RA, Cook JJ, Booag DM, Chang CT, Gaul SL, McQueney PA, Egbertson MS, Hartman GD. Holahan MA. Drug-dependent antibodies against GPIIb-IIIa induce thrombocytopenia. Circulation 1996; 94: I-99.
27. Du X, Plow EF, Frelinger AL, O'Toole TE, Loftus JC, Ginsberg MH. Ligands "activate" integrin aIIbb3 (platelet GPIIb-IIIa). Cell 1991; 65: 409-16.
28. Du X, Ginsberg MH. Integrin aIIbb3 and platelet function. Thromb Haemost 1997; 78: 96-100.
29. Ginsberg MH. Integrins: dynamic regulation of ligand binding. Biochem Soc Trans 1995; 23: 439-46.
30. Plow EF, D'Souza SE, Ginsberg MH. Consequences of the interaction of platelet membrane glycoprotein GPIIb-IIIa and its ligands. J Lab Clin Med 1992; 120: 198-204.
31. Shattil SJ, Ginsberg MH. Integrin signaling in vascular biology. J Clin Invest 1997; 100: 1-5.
32. Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in blood platelets. Curr Opin Cell Biol 1994; 6: 695-704.
33. Richardson A, Parsons JT. Signal transduction through integrins: a central role for focal adhesion kinase. BioEssays 1995; 17: 229-36.
34. Nurden AT. Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Thromb Haemost 1995; 74: 345-51.
35. Newman PJ. Platelet GPIIb-IIIa: molecular variations and alloantigens. Thromb Haemost 1991; 66: 111-8.
36. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PF. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.